港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

軒竹生物-B

30.100

+1.1003.79%

成交量：324.36萬

成交額：1.04億

市值：155.90億

市盈率：- -

高：33.960

開：28.000

低：28.000

收：29.000

52周最高：33.960

52周最低：23.820

股本：5.18億

香港流通股本：1.61億

量比：0.57

換手率：2.02%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：16.91

市盈率(LYR):- -

市銷率: 447.47

資料載入中...

總覽公司新聞公告

軒竹生物XZP - 7797 - H1片啓動Ⅰ期臨牀適應症為晚期實體瘤

軒竹生物將在港上市：募資淨額約7億港元，曾擬在A股募資約25億元

【新股IPO】國元國際指軒竹生物(02575)管線有一定的競爭力

港股IPO動態：今日長風藥業上市

港股異動 | 四環醫藥(00460)再漲超4% 軒竹生物今起招股公司旗下「凍妍」獲批上市

BRIEF-中國生物製藥公司軒竹生物擬在香港IPO籌7.8億港元

新股招股｜軒竹生物-B今起招股，一手入場費5858.5港元

老虎资讯综合

軒竹生物-B(02575)10月6日至10月10日招股預計10月15日上市

軒竹生物通過港交所聆訊，上市進入倒計時

軒竹生物通過港股上市聆訊，已有兩款產品實現商業化

軒竹生物港交所上市在即已商業化產品面臨激烈競爭

科创板日报记者史士云

軒竹生物通過港交所聆訊將上市；弘星相和完成近億元Pre-A輪孖展

每日经济新闻

軒竹生物通過港交所聆訊，四環醫藥通過子公司持股約56.47%

证券时报网

軒竹生物通過上市聆訊：年虧損5.6億陽光人壽退出股東行列

軒竹生物通過港交所聆訊，分拆自四環醫藥，有超過十種藥物資產在積極開發中

独角兽早知道

新股消息 | 軒竹生物通過港交所聆訊首款獲批產品KBP-3571已取得商業化收入

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02575/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"軒竹生物-B","latestPrice":30.1,"timestamp":1760681211993,"preClose":29,"halted":0,"volume":3243627,"delay":0,"floatShares":160701996,"shares":517947790,"eps":0,"marketStatus":"交易中","change":1.1,"latestTime":"10-17 14:07:03","open":28,"high":33.96,"low":28,"amount":103602515,"amplitude":0.205517,"askPrice":30.26,"askSize":1500,"bidPrice":30.1,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1760688600000},"marketStatusCode":2,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":29,"openAndCloseTimeList":[[1760664600000,1760673600000],[1760677200000,1760688000000]],"volumeRatio":0.573007,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":160701996,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.573007,"shares":517947790,"dividePrice":0,"high":33.96,"amplitude":0.205517,"preClose":29,"low":28,"week52Low":23.82,"pbRate":"16.91","psRate":"447.47","week52High":33.96,"institutionHeld":0,"latestPrice":30.1,"eps":0,"divideRate":0,"volume":3243627,"delay":0,"ttmEps":0,"open":28,"prevYearClose":11.6,"prevWeekClose":11.6,"prevMonthClose":11.6,"prevQuarterClose":11.6,"fiveDayClose":11.6,"twentyDayClose":11.6,"sixtyDayClose":11.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2025-10-15","current":-22.444691,"percent":1,"low":-22.444691,"twenty":-22.444691,"median":-22.444691,"eighty":-22.444691,"high":-22.444691,"avg":-22.444691,"sd":0,"marketCap":13622026877},"quantilePoints":[{"date":"2025-10-15","current":-22.444691,"twenty":-22.444691,"median":-22.444691,"eighty":-22.444691,"marketCap":13622026877}],"updateTime":1760642413208},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2574339934","title":"軒竹生物XZP - 7797 - H1片啓動Ⅰ期臨牀 適應症為晚期實體瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2574339934","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574339934?lang=zh_tw&edition=fundamental","pubTime":"2025-10-11 12:31","pubTimestamp":1760157060,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，轩竹生物科技股份有限公司/山东轩竹医药科技有限公司的评估XZP - 7797 - H1治疗晚期实体瘤受试者的安全性、耐受性、药代动力学特征和初步疗效的开放、多中心I期临床研究已启动。XZP - 7797 - H1片为化学药物，适应症为晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101112371694c2a6be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101112371694c2a6be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":1},{"id":"2574123546","title":"軒竹生物將在港上市：募資淨額約7億港元，曾擬在A股募資約25億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574123546","media":"贝多财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574123546?lang=zh_tw&edition=fundamental","pubTime":"2025-10-10 15:44","pubTimestamp":1760082240,"startTime":"0","endTime":"0","summary":"本次上市，轩竹生物拟定的发售价为每股11.60港元，募资总额约为7.81亿港元，募资净额约为7.01亿港元。据贝多商业&贝多财经了解，轩竹生物曾于2022年在上海证券交易所递交招股书，报考在科创板上市，原计划募资24.70亿元。2023年3月，轩竹生物上会但被暂缓审议。因此，该公司决定寻求H股于港交所上市。四环医药在此前公告中称，上市完成后，轩竹生物将仍为四环医药的附属公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101015461094c18ebb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101015461094c18ebb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","02575"],"gpt_icon":1},{"id":"2574822941","title":"【新股IPO】國元國際指軒竹生物(02575)管線有一定的競爭力","url":"https://stock-news.laohu8.com/highlight/detail?id=2574822941","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574822941?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 13:44","pubTimestamp":1759988675,"startTime":"0","endTime":"0","summary":"针对成人反流性食管炎的III期临床于2025年7月启动。同时，于2025年4月提交联合芳香化酶抑制NDA申请，预计2026年第三季度获批上市。XZP-3621：已获NDA批准，治疗ALK阳性晚期非小细胞肺癌，于2025年8月获批上市，并于2025年第四季度开始商业化。发行后市值为61亿港元，公司管线有一定的竞争力。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/MTFmM2Q2MTRhOWM5YmViYzgzOWMzMDFlOWYzNjEzNTY0MjA2MzIx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MTFmM2Q2MTRhOWM5YmViYzgzOWMzMDFlOWYzNjEzNTY0MjA2MzIx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1967478","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":1},{"id":"2573921508","title":"港股IPO動態：今日長風藥業上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2573921508","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573921508?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 06:09","pubTimestamp":1759874999,"startTime":"0","endTime":"0","summary":"格隆汇10月8日｜今日长风药业(2652.HK)上市，轩竹生物-B(2575.HK)申购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100806113394be559b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100806113394be559b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","02575"],"gpt_icon":0},{"id":"2573624330","title":"港股異動 | 四環醫藥(00460)再漲超4% 軒竹生物今起招股 公司旗下「凍妍」獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2573624330","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573624330?lang=zh_tw&edition=fundamental","pubTime":"2025-10-06 14:28","pubTimestamp":1759732136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药(00460)再涨超4%，截至发稿，涨4.47%，报1.87港元，成交额6651.81万港元。消息面上，轩竹生物于10月6日至10月10日招股，该公司拟全球发售6733.35万股，预期股份将于10月15日在联交所开始买卖。据悉，轩竹生物分拆自四环医药。此外，四环医药旗下渼颜空间自主研发的“注射用透明质酸钠复合溶液——冻妍”近日获得国家药监局三类医疗器械注册证，标志着国内首款含L-肌肽复合溶液水光针正式登陆资本市场视野。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d26aa812aba485e9cce82e67f394d390","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1600","BK4614","02575","00460","BK1593","YANG","BK1515"],"gpt_icon":0},{"id":"2573647851","title":"BRIEF-中國生物製藥公司軒竹生物擬在香港IPO籌7.8億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573647851","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573647851?lang=zh_tw&edition=fundamental","pubTime":"2025-10-06 09:02","pubTimestamp":1759712526,"startTime":"0","endTime":"0","summary":"BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元路透香港10月6日 - 中国生物制药公司--轩竹生物科技股份有限公司2575.HK：* 全球发售6,733.35万股H股股份，发售价每股11.6港元，10月6日开始香港公开发售，预期10月15日在联交所开始买卖；独家保荐人为中金公司* 我们有三款核心产品，即KBP-3571（已获NDA批准的治疗消化系统疾病的创新质子泵抑制剂(PPI)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nL3T3VN01K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1600","02575","BK1593","00460","BK1515"],"gpt_icon":0},{"id":"1173249988","title":"新股招股｜軒竹生物-B今起招股，一手入場費5858.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173249988","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173249988?lang=zh_tw&edition=fundamental","pubTime":"2025-10-06 07:41","pubTimestamp":1759707686,"startTime":"0","endTime":"0","summary":"10月6日，$轩竹生物-B$于10月6日至10月10日招股，该公司拟全球发售6733.35万股，其中香港发售占10%，国际发售占90%，另有15%超额配股权，每股发售价11.6港元。申购阶梯：每手500股，入场费5858.5港元。乙组门槛为50万股，申购所需资金约585.85万港元。基于发售价每股发售股份11.60港元，基石投资者将认购的发售股份数目为660.3万股。","market":"hk","thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜轩竹生物-B今起招股，一手入场费5858.5港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"2573641931","title":"軒竹生物-B(02575)10月6日至10月10日招股 預計10月15日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2573641931","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573641931?lang=zh_tw&edition=fundamental","pubTime":"2025-10-06 07:13","pubTimestamp":1759706024,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 于2025年10月6日至10月10日招股，该公司拟全球发售6733.35万股，其中香港发售占10%，国际发售占90%，另有15%超额配股权，每股发售价11.6港元。每手500股，预期股份将于2025年10月15日在联交所开始买卖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PPI","BK4588","02575","BK4585","ALK","BK4500","BK4570","BK4008"],"gpt_icon":0},{"id":"2569727684","title":"軒竹生物通過港交所聆訊，上市進入倒計時","url":"https://stock-news.laohu8.com/highlight/detail?id=2569727684","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569727684?lang=zh_tw&edition=fundamental","pubTime":"2025-09-22 07:32","pubTimestamp":1758497550,"startTime":"0","endTime":"0","summary":"据港交所9月17日披露，总部位于北京、注册于河北石家庄、分拆自四环医药轩竹生物科技股份有限公司通过港交所主板上市聆讯即将上市，中金公司为独家保荐人。此外，轩竹生物已成功完成三轮股权融资，筹集资金约人民币16亿元，投资者包括国投招商投资管理有限公司，后者在公司发行的股本总额中占有约20.72%的股份。从股东结构来看，轩竹生物的控股股东包括四环医药控股集团及其关联方。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922074027a43afa5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922074027a43afa5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0856984785.SGD","LU0061477393.USD","LU0165289439.USD","BK1610","LU1734074674.USD","LU1504937902.USD","LU1282649067.USD","IE00B3T34201.USD","LU0516422952.EUR","LU0540923850.HKD","LU0762540952.USD","LU0348814723.USD","LU0348735423.USD","LU0561508036.HKD","LU1831875114.USD","LU0791591158.USD","LU1328277881.USD","LU0634319403.HKD","LU1242518931.SGD","LU0048597586.USD","SGXZ90724238.SGD","LU0117841782.USD","LU1366334651.USD","LU1481107354.HKD","02575","LU0797268264.HKD","LU0196878994.USD","LU0594300419.USD","LU1813983027.USD","LU1807302812.USD","LU1282649141.HKD","SG9999001846.SGD","LU0140636845.USD","LU0651947912.USD","LU1981816686.USD","IE00BZ08YS42.EUR","LU0791590937.USD","LU1282649810.SGD","LU0384037296.USD","LU0359201885.HKD","LU0096374516.USD","LU0831103253.SGD","LU0516423174.USD","LU0979878070.USD","LU0211977185.USD","LU0072462343.USD","LU0149721374.USD"],"gpt_icon":0},{"id":"2568290570","title":"軒竹生物通過港股上市聆訊，已有兩款產品實現商業化","url":"https://stock-news.laohu8.com/highlight/detail?id=2568290570","media":"贝多财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568290570?lang=zh_tw&edition=fundamental","pubTime":"2025-09-20 08:25","pubTimestamp":1758327910,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K9SSHP9B0539JGBD.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K9SSHP9B0539JGBD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02575"],"gpt_icon":0},{"id":"2568828266","title":"軒竹生物港交所上市在即 已商業化產品面臨激烈競爭","url":"https://stock-news.laohu8.com/highlight/detail?id=2568828266","media":"科创板日报记者 史士云","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568828266?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 08:21","pubTimestamp":1758241260,"startTime":"0","endTime":"0","summary":"①港股上市条件更为灵活，流程周期也更短，凭借国际化属性可吸引全球资本的关注，企业上市后通常能获得更高的估值溢价；\n②对于一款上市一年多的国创新药而言，其累计三千多万元的销售额，与行业内那些年销售额动辄破亿元的创新产品相比，着实算不上惊艳。。","market":"hk","thumbnail":"https://img.cls.cn/images/20250919/SdPfb98Rn5_1024x683.jpg","type":0,"news_type":0,"thumbnails":["https://img.cls.cn/images/20250919/SdPfb98Rn5_1024x683.jpg"],"rights":{"source":"starmarket_stock","url":"https://www.chinastarmarket.cn/detail/2149697","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chinastarmarket.cn/detail/2149697","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"starmarket_stock","symbols":["BK1600","02575","BK0239","BK1593","BK1515","BK1191"],"gpt_icon":0},{"id":"2568281637","title":"軒竹生物通過港交所聆訊將上市；弘星相和完成近億元Pre-A輪孖展","url":"https://stock-news.laohu8.com/highlight/detail?id=2568281637","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568281637?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 07:13","pubTimestamp":1758237180,"startTime":"0","endTime":"0","summary":"| 2025年9月19日星期五丨 NO.1复宏汉霖CDK4/6抑制剂在中国获批新适应证复宏汉霖宣布，创新型CDK4/6抑制剂枸橼酸伏维西利胶囊新增适应证的药品注册申请获得中国国家药品监督管理局(NMPA)批准 ...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20250919/c671256019.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250919/c671256019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02575"],"gpt_icon":0},{"id":"2568940602","title":"軒竹生物通過港交所聆訊，四環醫藥通過子公司持股約56.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568940602","media":"证券时报网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568940602?lang=zh_tw&edition=fundamental","pubTime":"2025-09-18 23:03","pubTimestamp":1758207780,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司(以下简称“轩竹生物”)日前通过港交所主板上市聆讯，中金公司担任独家保荐人。轩竹生物的控股股东为四环医药控股集团有限公司(以下简称“四环医药”)，通过其间接 ...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20250918/c671254120.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250918/c671254120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02575"],"gpt_icon":0},{"id":"2568449159","title":"軒竹生物通過上市聆訊：年虧損5.6億 陽光人壽退出股東行列","url":"https://stock-news.laohu8.com/highlight/detail?id=2568449159","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568449159?lang=zh_tw&edition=fundamental","pubTime":"2025-09-18 09:10","pubTimestamp":1758157832,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司（简称：“轩竹生物”）日前通过上市聆讯，准备在港交所上市。招股书显示，轩竹生物2022年、2023年期内亏损分别为5.12亿元、3亿元、5.56亿元；","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250918/6389378338361001822049266.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250918/6389378338361001822049266.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n31228/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["02575"],"gpt_icon":0},{"id":"2568282630","title":"軒竹生物通過港交所聆訊，分拆自四環醫藥，有超過十種藥物資產在積極開發中","url":"https://stock-news.laohu8.com/highlight/detail?id=2568282630","media":"独角兽早知道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568282630?lang=zh_tw&edition=fundamental","pubTime":"2025-09-18 08:10","pubTimestamp":1758154200,"startTime":"0","endTime":"0","summary":"截至最后实际可行日期，轩竹生物有超过十种药物资产在积极开发中，涵盖消化系统疾病、肿瘤和非酒精性脂肪性肝炎，包括三项NDA批准资产，一个药物项目处于NDA注册阶段，一个药物项目处于III期临床试验阶段，四个药物项目处于I期临床试验阶段，五个已获IND批准。截至最后实际可行日期，公司已建立一条管线，其下有超过十种药物资产在积极开发中，包括三款核心产品及四款关键产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU3MTY1MzExOQ==&mid=2247599363&idx=1&sn=21559db1b2069e9d5c9331fef431b308&chksm=fdcf37950d3a7d7a9e486779a3e56c1315e386898cb7dbd3117cb677a03639cc95b4cc68870a&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1600","BK1515","02575","BK1593"],"gpt_icon":0},{"id":"2568480744","title":"新股消息 | 軒竹生物通過港交所聆訊 首款獲批產品KBP-3571已取得商業化收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2568480744","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568480744?lang=zh_tw&edition=fundamental","pubTime":"2025-09-18 06:44","pubTimestamp":1758149086,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}]}}